Today, the FDA expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients 12 years of age and older after contact with an individual who has the flu.
Read more: FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention